Brachytherapy is a Promising Treatment for Prostate Cancer


Cite item

Full Text

Abstract

Abstract – prostate Cancer is one of the most common cancers among men. Incidence is second only to tumors of the broncho-  pulmonary system. In recent years significantly increased the interest in contact radiation methods of treatment of this disease (brachytherapy). In the treatment of prostate cancer there is experience of application of different source of dose-rate  used sources of low dose (isotopes of iodine (125I), palladium (103Pd) and cesium (131Cs) and sources used for high dose rate (iridium Ir192 or cobalt 60 Co). In Russia the greatest popularity is the use of isotope Ir192 andI125 for brachytherapy. Given indentichnost the indications for treatment, equivalent figures cancerspecifically and relapse-free survival, the question of the choice of treatment is very important. A brief review of the literature on the use of brachytherapy for prostate cancer sources of different dose. Presents comparative characteristics of treatment results, complications, early and late toxic reactions when used brachytherapy isotopes different dose.

About the authors

Dmitry Yurievich Kamenev

Voronezh state medical University n.  N. N. Burdenko;
BUZ VO "Voronezh regional clinical oncologic dispensary"
 

Author for correspondence.
Email: kamenev_dmitrii@mail.ru
SPIN-code: 2478-7289

assistant Professor of Oncology IDPO VSMU them. N. N. Burdenko; oncologist, radiologist BUZ VO BOKOD

Russian Federation,  Studencheskaya Str. 10, Voronezh, 394036, Russian Federation

Ivan Petrovich Moshurov

Voronezh state medical University n.  N. N. Burdenko;
BUZ VO "Voronezh regional clinical oncologic dispensary"

Email: moshurov@vokod.vrn.ru

head of Department of Oncology IDPO VSMU them. N. N. Burdenko, head doctor of BUZ VO BOKOD

Russian Federation, Studencheskaya Str. 10, Voronezh, 394036, Russian Federation

Bronislava Borisovna Kravets

Voronezh state medical University n.  N. N. Burdenko;
BUZ VO "Voronezh regional clinical oncologic dispensary"

Email: kravets@vokod.ru

MD, Professor, Department of Oncology IDPO, Deputy chief physician BUZ IN BOKOD

Russian Federation, Studencheskaya Str. 10, Voronezh, 394036, Russian Federation

Nataliya Viktorovna Korotkikh

Voronezh state medical University n.  N. N. Burdenko;
BUZ VO "Voronezh regional clinical oncologic dispensary"

Email: kornat78@mail.ru

PhD, assistant Professor of Oncology IDPO, head of the radiology Department N 5

Russian Federation, Studencheskaya Str. 10, Voronezh, 394036, Russian Federation

References

  1. Alekseev B. Ya., Kaprin A. D., Matveev V. B., Nyushko K. M.. Clinical recommendations for the diagnosis and treatment of patients with prostate cancer. Moscow, 2014; 22.
  2. Biryukov V. A., Karyakin O. B., Morow O. V., Lepilina O. G., Naletov D. V., Sanin, D. B., Grishin G. N., Kalinina M. S. low-Dose brachytherapy in the combined treatment of patients with intermediate risk localized prostate cancer // Research and practice in medicine. 2014; 1:1: 29-34.
  3. Gerasimov A. A. minimally Invasive methods of radical treatment of patients with prostate cancer of intermediate and poor prognostic groups, Diss. Cand. med. Sciences. Moscow 2014; 17
  4. Zyryanov A.V., Oshchepkov V. N., Sviridov P. V., Baranov A. V., Biryukov V. A., Korotkov V. A., Wisniski A. A., Gorelov V. P., Gusmanov R. I., Dadashev, E. A., Zabolotnov Yu K., Zagidullin, A. A., Zaitsev A. V., Zuev, O. V., Ivanov V. Yu., Karnaukh P. A., Koryakin V. A., Morow O. V., A. D. Cybulski. etc. Recommendations for the treatment of prostate cancer with permanent interstitial low-dose radiation therapy (brachytherapy) // Oncourology. Expert and clinical urology. 2015; 2: 37-46.
  5. Kaprin A. D., Panshin G. A. Interstitial radiation therapy of prostate cancer using high dose rate Ir 192 (medical technology). Moscow, 2010; 18.
  6. Kaprin A. D., Panshin G. A., Al'bitskiy, I. A., Milenin, K. N., Khmelevsky E. V. the Role of brachytherapy in the radical treatment of prostate cancer. The journal "Issues of Oncology", 2006;52:5: 600-604.
  7. Novikov, S. N., Kanaev, S. V., Novikov, R. V., Il'in, N. D., Gotovchikov, M. Y. high-dose brachytherapy for prostate cancer in real time using source 192-IR (dosimetric planning) Qu. Oncol.- 2015; 61:1:130-136.
  8. SOLODKY V. A., Pavlov A. Yu., Panshin G. A., Cybulski A. D. Kravtsov, I. B., Isaev T. K. Brachytherapy for prostate cancer with the use of temporary sources; mono// Vopr.Oncol.-2016;62:5:611-614.
  9. Sycheva I. V., Passes V. V., A. K. Kurpesheva Conservative methods of treatment of local radiation injuries resulting combined radiation therapy and brachytherapy of prostate cancer. Siberian journal of Oncology. 2012;5:53:57-60.
  10. Kharchenko V. P. Kaprin A. D., Panshin G. A., K. P. Milenin, I. A. Albitsky, Zygulski A. D.. Brachytherapy is a modern method of radical treatment of localized prostate cancer // Radiology - practice. 2008;6:35-39.
  11. Chernyshev, I. V., Samsonov Yu. V., Perepechin D. V., Koryakin V. A., Osipov O. V. Quality of life and social adaptation of patients after radical prostatectomy and interstitial radiation therapy [Journal] Modern methods of treatment of urological diseases. – 2013;106-108.
  12. Davis B.J. Horwitz EM, Lee WR, Crook JM, Stock RG, Merrick GS. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. // Brachytherapy. 2012;11:1:6–19.
  13. Demanes D.J., Ghilezan M.I. High-dose-rate brachytherapy as monotherapy for prostate cancer. // Brachytherapy. 2014;13(6): 529-541.
  14. Dickinson P.D. Jahangeer Malik, Paula Mandall, Ric Swindell, David Bottomley, Peter Hoskin, John P. Logue, James P. Wylie. Five-year outcomes after iodine-125 seed brachytherapy for low-risk prostate cancer at three cancer centres in the UK. // BJU Int. 2014;113:5:748–53.
  15. Galalae RM, Zakikhany NH, Geiger F. The 15-year outcomes of high-dose-rate brachytherapy for radical dose escalation in patients with prostate cancer - a benchmark for high-tech external beam radiotherapy alone? Brachytherapy 2014;13(2):117-122.
  16. Ghilezan M. Role of high dose rate brachytherapy in the treatment of prostate cancer. // Cancer Radiother. 2012 Sep;16(5-6):418-22.
  17. Giberti C. L. Chiono, F. Gallo, M. Schenone, E. Gastaldi. Radical retropubic prostatectomy versus brachytherapy for low-risk prostatic cancer: a prospective study. // World J. Urol. 2009; 27:5:607–12.
  18. Heidenreich A. M. Bolla, S. Joniau, M.D. Mason, V. Matveev, N. Mottet, H-P. Schmid, T.H. van der Kwast, T. Wiegel, F. Zattoni. Рак предстательной железы / под ред. Б.Я. Алексеев, В.Б. Матвеев. : Европейская ассоциация урологов, 2011;29.
  19. Henry AM, Al-Qaisieh B, Gould K, Bownes P, Smith J, Carey B, Bottomley D, Ash D. Outcomes following iodine-125 monotherapy for localized prostate cancer: the results of leeds 10-year single-center brachytherapy experience. Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):50-6.
  20. Hsu I.-C. Bae K, Shinohara K, Pouliot J, Purdy J, Ibbott G, Speight J, Vigneault E, Ivker R, Sandler H. Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321. Int. J. Radiat. Oncol. Biol. Phys. 2010;78:3:751–8.
  21. Kang S.K. Acute urinary toxicity following transperineal prostate brachytherapy using a modified Quimby loading method. Int. J. Radiat. Oncol. Biol. Phys. 2001;50:937–45.
  22. Keyes M. Treatment options for localized prostate cancer. Can. Fam. Physician. 2013;59:12:1269–74.
  23. Kovács G. Galalae R, Loch T, Bertermann H, Kohr P, Schneider R. Prostate preservation by combined external beam and HDR brachytherapy in nodal negative prostate cancer. // Strahlenther. Onkol. 1999;175:87–8.
  24. Li G. A Fully Actuated Robotic Assistant for MRI-Guided Prostate Biopsy and Brachytherapy. // Proc. Soc. Photo. Opt. Instrum. Eng. 2013;8671:867117.
  25. McElveen T.L., Waterman F.M. Factors predicting for urinary incontinence after prostate brachytherapy// Int J Radiat Oncol Biol Phys.-2004 Aug.-1.-59(5).-1395-404.
  26. Nag S, Beyer D, Friedland J. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 1999; 44: 4: 789–99.
  27. Pellizzon A.C.A. High-dose-rate brachytherapy combined with hypofractionated external beam radiotherapy for men with intermediate or high risk prostate cancer: analysis of short- and medium-term urinary toxicity and biochemical control. Int. J. Clin. Exp. Med. 2011;4:1:43–52.
  28. Petasecca M. и др. BrachyView: proof-of-principle of a novel in-body gamma camera for low dose-rate prostate brachytherapy. Med. Phys. 2013;40:4:041709.124.
  29. Prada PJ, Juan G, González-Suárez H, Fernández J, Jimenez I, Amón J, Cepeda M. Prostate-specific antigen relapse-free survival and side-effects in 734 patients with up to 10 years of follow-up with localized prostate cancer treated by permanent iodine implants. BJU Int. 2010 Jul;106(1):32-6. Epub 2010 Jan 8.
  30. Rogers CL, Alder SC, Rogers RL, Hopkins SA, Platt ML, Childs LC, Crouch RH, Hansen RS, Hayes JK. High dose brachytherapy as monotherapy for intermediate risk prostate cancer. J Urol. 2012 Jan;187(1):109-16. Epub 2011 Nov 16.
  31. Rodrigues G.. Evidence-based guideline recommendations on low-dose rate brachytherapy in patients with low- or intermediate-risk prostate cancer. Can. Urol. Assoc. J. 2013a;7:5-6:E411–6.
  32. Rodrigues G, Yao X, Loblaw DA, Brundage M, Chin JL. Low-dose rate brachytherapy for patients with low- or intermediate-risk prostate cancer: A systematic review. Can. Urol. Assoc. J. 2013b; 7:11-12: 463–70.
  33. Skowronek J. Brachytherapy in the therapy of prostate cancer - an interesting choice. Contemp. Oncol. (Poznań, Poland). 2013a;17:5:407–12.
  34. Skowronek J. Low-dose-rate or high-dose-rate brachytherapy in treatment of prostate cancer - between options. J. Contemp. Brachytherapy. 2013b;5:1:33–41.
  35. Whaley JT, Levy LB, Swanson DA, Pugh TJ, Kudchadker RJ, Bruno TL, Frank SJ. Sexual function and the use of medical devices or drugs to optimize potency after prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):e765-71. Epub 2012 Jan 31.
  36. Yamada Y, Rogers L, Demanes DJ, Morton G, Prestidge BR, Pouliot J, Cohen GN, Zaider M, Ghilezan M, Hsu IC; American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy // Brachytherapy. 2012 Jan-Feb;11(1):20-32.
  37. Yorozu, A., Kuroiwa, N., Takahashi, A., Toya, K., Saito, S., Nishiyama, T., Yagi, Y., Tanaka, T., Shiraishi, Y. & Ohashi, T. Permanent prostate brachytherapy with or without supplemental external beam radiotherapy as practiced in Japan: Outcomes of 1300 patients. Brachytherapy. 2015.
  38. Zamboglou N, Tselis N, Baltas D, Buhleier T, Martin T, Milickovic N, Papaioannou S, Ackermann H, Tunn UW. High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature results. Int J Radiat Oncol Biol Phys 2013;;85(3):672-678.
  39. Zhang LL, Ma L, Tian JH, Ren YY, Yang KH. [(125)I versus (103)Pd brachytherapy for low risk prostate cancer: a systematic review]. Ai Zheng. 2009;28:8:872–8.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Kamenev D.Y., Moshurov I.P., Kravets B.B., Korotkikh N.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies